• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by Vesper Healthcare Acquisition Corp.

    5/18/21 4:26:54 PM ET
    $VSPR
    Business Services
    Finance
    Get the next $VSPR alert in real time by email
    NT 10-Q 1 beautyhealth-12b25q12021.htm NT 10-Q Document


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549
    FORM 12b-25
    NOTIFICATION OF LATE FILING
    (Check One):
    ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q
    ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR
    For Period Ended:      March 31, 2021     
    ☐ Transition Report on Form 10-K
    ☐ Transition Report on Form 20-F
    ☐ Transition Report on Form 11-K
    ☐ Transition Report on Form 10-Q
    For the Transition Period Ended:
    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: Not Applicable
    PART I – REGISTRANT INFORMATION
    The Beauty Health Company
    Full Name of Registrant
    Vesper Healthcare Acquisition Corp.
    Former Name if Applicable
    2165 Spring Street
    Address of Principal Executive Office (Street and Number)
    Long Beach, CA 90806
    City, State and Zip Code
    PART II – RULES 12b-25(b) AND (c)
    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
    ☐
    (a)
    The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
    (b)
    The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
    (c)
    The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.




    PART III – NARRATIVE
    State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
    (Attached extra Sheets if Needed)
    The Beauty Health Company (the “Company”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021 (the “Q1 2021 Form 10-Q”) by the prescribed due date for the reasons described below.
    In light of the Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (“SPACs”) (the “Staff Statement”) issued by the staff of the Securities and Exchange Commission on April 12, 2021, the Audit Committee of the Company’s Board of Directors, together with management, has determined that the Company’s consolidated financial statements and related notes for the fiscal year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 18, 2021 (the “Original Form 10-K”) should be restated.
    The Company is working diligently to complete the Q1 2021 Form 10-Q as soon as possible and will file the Q1 2021 Form 10-Q as soon as reasonably practicable; however, given the scope of the process for evaluating the impact of the Staff Statement on the Company’s financial statements and the Company’s management’s focus on preparing an amendment to the Original Form 10-K containing restated financial statements for the year ended December 31, 2020, the Company is unable to complete and file the Q1 2021 Form 10-Q by the required due date of May 17, 2021 without unreasonable effort and expense.
    PART IV – OTHER INFORMATION
    (1)Name and telephone number of person to contact in regard to this notification:
    Liyuan Woo
    800
    603-4996
    (Name)(Area code)(Telephone Number)
    (2)
    Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
    ☒ Yes ☐ No
    (3)
    Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
    ☐ Yes ☒ No
    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.




    The Beauty Health Company
    (Name of Registrant as Specified in Charter)
    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
    Date: May 18, 2021
    By:/s/ Liyuan Woo
    Liyuan Woo
    Chief Financial Officer


    Get the next $VSPR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VSPR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VSPR
    SEC Filings

    View All

    SEC Form 4 filed by Vesper Healthcare Acquisition Corp.

    4 - Beauty Health Co (0001818093) (Issuer)

    5/21/21 8:00:45 PM ET
    $VSPR
    Business Services
    Finance

    SEC Form 4 filed by Vesper Healthcare Acquisition Corp.

    4 - Beauty Health Co (0001818093) (Issuer)

    5/21/21 7:59:07 PM ET
    $VSPR
    Business Services
    Finance

    SEC Form 8-K filed by Vesper Healthcare Acquisition Corp.

    8-K - Beauty Health Co (0001818093) (Filer)

    5/20/21 4:07:22 PM ET
    $VSPR
    Business Services
    Finance

    $VSPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    DA Davidson initiated coverage on Vesper Healthcare Acquisition Corp. with a new price target

    DA Davidson initiated coverage of Vesper Healthcare Acquisition Corp. with a rating of Buy and set a new price target of $15.50

    4/13/21 6:59:11 AM ET
    $VSPR
    Business Services
    Finance

    The Benchmark Company initiated coverage on Vesper Healthcare Acquisition Corp. with a new price target

    The Benchmark Company initiated coverage of Vesper Healthcare Acquisition Corp. with a rating of Buy and set a new price target of $16.00

    3/18/21 7:41:55 AM ET
    $VSPR
    Business Services
    Finance

    Benchmark initiated coverage on Vesper Healthcare with a new price target

    Benchmark initiated coverage of Vesper Healthcare with a rating of Buy and set a new price target of $16.00

    3/18/21 6:57:43 AM ET
    $VSPR
    Business Services
    Finance

    $VSPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Linden and DW Healthcare Partners Complete HydraFacial's Public Offering via SPAC Merger

    CHICAGO and PARK CITY, Utah, May 5, 2021 /PRNewswire/ -- Linden Capital Partners ("Linden") and DW Healthcare Partners IV, LP ("DW Healthcare Partners"), both private equity firms focused exclusively on the healthcare sector, announced today the completion of the merger of Edge Systems, LLC ("HydraFacial"), a category-creating beauty health company, with Vesper Healthcare Acquisition Corp. (NASDAQ:VSPR) ("Vesper" or "Vesper Healthcare"). Vesper is a special purpose acquisition company ("SPAC") led by former Allergan CEO Brent Saunders. As a result of the transaction, the combined company, now known as The Beauty Health Company ("BeautyHealth" or the "Company"), is expected to trade on the Na

    5/5/21 7:30:00 AM ET
    $VSPR
    Business Services
    Finance

    HydraFacial Announces Record First Quarter Fiscal 2021 Preliminary Net Sales

    First Quarter 2021 Preliminary Financial Highlights: Q1 net sales of $47 million compared to $33 million in Q1 2020 and $35 million in Q1 2019 Q1 net sales in the Americas region of $31 million, or 66% of total net sales, compared to $24 million in Q1 2020 and $27 million in Q1 2019 Q1 net sales in the EMEA and APAC regions of $16 million, or 34% of total sales, compared to $9 million in Q1 2020 and $8 million in Q1 2019 The HydraFacial® Company ("HydraFacial," or the "Company"), an experiential category-creating beauty health company, today announced preliminary net sales for the quarter ended March 31, 2021. The Company has not yet completed the quarter-end review and expects to r

    4/21/21 6:45:00 AM ET
    $VSPR
    Business Services
    Finance

    HydraFacial, a Beauty Health Company, Announces 2020 Preliminary Net Sales

    MIAMI BEACH, Fla. & LONG BEACH, Calif.--(BUSINESS WIRE)--The HydraFacial® Company (“HydraFacial,” or the “Company”), a category-creating beauty health company, today announced preliminary net sales for the fiscal year ended December 31, 2020. HydraFacial currently expects net sales for fiscal year 2020 to approximate $119 million. The Company’s previous expectation for net sales, provided on December 9, 2020, was approximately $115 million. The Company has not yet completed the year-end audit and expects to report full results for fiscal year 2020 at a future date. The previously announced business combination with Vesper Healthcare (NASDAQ: VSPR) remains on track to be completed

    2/22/21 6:45:00 AM ET
    $VSPR
    Business Services
    Finance

    $VSPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Woo Liyuan

    4 - Beauty Health Co (0001818093) (Issuer)

    5/21/21 8:00:17 PM ET
    $VSPR
    Business Services
    Finance

    SEC Form 4 filed by LCP Edge Holdco LLC

    4 - Beauty Health Co (0001818093) (Issuer)

    5/21/21 4:34:28 PM ET
    $VSPR
    Business Services
    Finance

    SEC Form 4 filed by SAUNDERS BRENT L

    4 - Beauty Health Co (0001818093) (Issuer)

    5/18/21 9:22:28 PM ET
    $VSPR
    Business Services
    Finance

    $VSPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Vesper Healthcare Acquisition Corp. (Amendment)

    SC 13D/A - Beauty Health Co (0001818093) (Subject)

    5/21/21 4:30:37 PM ET
    $VSPR
    Business Services
    Finance

    SEC Form SC 13D filed by Vesper Healthcare Acquisition Corp.

    SC 13D - Beauty Health Co (0001818093) (Subject)

    5/14/21 4:23:32 PM ET
    $VSPR
    Business Services
    Finance

    SEC Form SC 13G filed

    SC 13G - Vesper Healthcare Acquisition Corp. (0001818093) (Subject)

    2/16/21 3:58:03 PM ET
    $VSPR
    Business Services
    Finance